Dark

ANAB
AnaptysBio, Inc. Common Stock
stock NASDAQ

At Close

May 30, 2025 3:59:56 PM EDT

22.22USD-1.507%(-0.34)683,007

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 30, 2025 8:54:30 AM EDT

22.51USD-0.222%(-0.05)290

After-hours

May 30, 2025 4:01:30 PM EDT

22.47USD+1.171%(+0.26)13,789

OverviewOptionsHistoricalExchangesShortsNews

Jan 6, 2022

08:00AM EST Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the establishment of its scientific advisory board. GlobeNewswire Inc

Jan 5, 2022

04:05PM EST AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Nov 29, 2021

04:06PM EST AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the companys Board of Directors. GlobeNewswire Inc

Nov 15, 2021

11:15AM EST AnaptysBio Announces Rosnilimab Healthy Volunteer Phase 1 Top-Line Data; Says Anti-PD-1 Agonist Antibody 'demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohorts' Benzinga

09:00AM EST AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 GlobeNewswire Inc

Nov 5, 2021

09:32AM EDT AnaptysBio Q3 EPS $(0.24) Up From $(0.87) YoY Benzinga

Oct 26, 2021

08:36AM EDT The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children Benzinga

Oct 25, 2021

04:39PM EDT AnaptysBio Reports Deal To Monetize Portion Of JEMPERLI Royalties For $250M With Sagard Benzinga

04:37PM EDT AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI GlobeNewswire Inc

Oct 4, 2021

03:06PM EDT AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis Benzinga

Oct 2, 2021

12:00PM EDT AnaptysBio Presents Updated Data From ImsidolimabPhase GlobeNewswire Inc

Sep 9, 2021

04:05PM EDT AnaptysBio to Participate in the H.C. Wainwright 23rd Annual GlobeNewswire Inc

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

07:00AM EDT AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication Benzinga

Aug 17, 2021

04:34PM EDT AnaptysBioFDA Grants Accelerated Approval Of GSK's JEMPERLI, Which Was Generated By AnaptysBio; Co. Has Earned $20M Milestone Payment As A Result Benzinga

04:32PM EDT FDA Grants Accelerated Approval of JEMPERLI GlobeNewswire Inc

Aug 9, 2021

05:10PM EDT AnaptysBio Q2 EPS $(0.02) Up From $(0.79) YoY, Sales $30.00M Benzinga

04:05PM EDT AnaptysBio Announces Second Quarter 2021 Financial Results GlobeNewswire Inc

Jun 22, 2021

09:12AM EDT HC Wainwright & Co. Initiates Coverage On AnaptysBio with Buy Rating, Announces Price Target of $43 Benzinga

May 27, 2021

04:15PM EDT AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare GlobeNewswire Inc

May 21, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 Benzinga

06:33AM EDT UBS Initiates Coverage On AnaptysBio with Neutral Rating, Announces Price Target of $29 Benzinga

May 8, 2021

12:10PM EDT The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More Benzinga

May 4, 2021

04:07PM EDT AnaptysBio Sees FY 2021 Net Cash Burn ~$100M Benzinga

04:06PM EDT AnaptysBio Q1 EPS $(0.66) Down From $(0.30) YoY Benzinga

04:05PM EDT AnaptysBio Announces First Quarter 2021 Financial Results GlobeNewswire Inc

May 2, 2021

08:05AM EDT Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More Benzinga

Apr 28, 2021

05:21AM EDT Anaptysbio Director Oleg Nodelman Reported Purchase of 147,300 Shares @ Avg Price of $23.63/Share in Form 4 Filing on Tuesday Benzinga

Apr 23, 2021

10:32AM EDT AnaptysBio Reports European Commission Has Approved JEMPERLI For Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe Benzinga

10:31AM EDT European Commission Approves JEMPERLI GlobeNewswire Inc

Apr 22, 2021

04:14PM EDT AnaptysBio Announces FDA Approval Of JEMPERLI For dMMR Endometrial Cancer Benzinga

04:12PM EDT FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer GlobeNewswire Inc

Apr 12, 2021

04:00PM EDT AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Oleg Nodelman to the companys Board of Directors. GlobeNewswire Inc

Mar 16, 2021

03:06PM EDT Why AnaptysBio Stock Is Attractive After 30% Selloff Benzinga

10:38AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2021 Benzinga

07:24AM EDT Truist Securities Upgrades AnaptysBio to Buy, Raises Price Target to $34 Benzinga

Mar 11, 2021

05:48AM EST Anaptysbio 10%+ Owner Ecor1 Capital, Llc Reported Purchase of 3,308,800 Shares @ Avg Price of $18.93/Share in Form 4 Filing on Wednesday Benzinga

Mar 9, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021 Benzinga

09:18AM EST Wedbush Downgrades AnaptysBio to Neutral Benzinga

Mar 8, 2021

02:38PM EST Mid-Afternoon Market Update: Nasdaq Drops Over 150 Points; Crude Oil Down 2% Benzinga

12:03PM EST Mid-Day Market Update: Dow Jumps 500 Points; AnaptysBio Shares Plunge Benzinga

10:25AM EST Shares of AnaptysBio, Inc. (ANAB) are down more than 34% Monday morning after the clinical-stage biotechnology company announced negative top-line results from the mid-stage study of its lead drug candidate imsidolimab, for the treatment of palmoplantar pustulosis. RTTNews

10:14AM EST Mid-Morning Market Update: Markets Gain; US Senate Clears $1.9 Trillion Covid-19 Relief Bill Benzinga

08:46AM EST AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in GlobeNewswire Inc

08:28AM EST AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study Benzinga

08:24AM EST AnaptysBio Says Imsidolimab POPLAR Phase 2 Clinical Trial In Moderate-To-Severe Palmoplantar Pustulosis Did Not Meet Primary Endpoint; Shares Halted On Code News Pending, Set To Resume At 8:30 a.m. EST Benzinga

Feb 25, 2021

04:59PM EST AnaptysBio Q4 EPS $1.20 Up From $(0.75) YoY, Sales $60.00M Up From $3.00M YoY Benzinga

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 11, 2021

10:42AM EST AnaptysBio Expects To Report Cash, Cash Equivalents, Investments Of ~$410M As Of Dec. 31, 2020 Benzinga

Jan 7, 2021

04:15PM EST AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Nov 17, 2020

04:12PM EST On Nov. 11, AnaptysBio Terminated Sublease With Trex Enterprises Corp. With Respect To Facilities In San Diego, CA Building Benzinga

Nov 13, 2020

09:25AM EST AnaptysBio to Present at the 2020 Jefferies London Virtual GlobeNewswire Inc

Nov 4, 2020

04:01PM EST AnaptysBio Q3 EPS $(1.96) Down From $(1.15) YoY Benzinga

04:00PM EST AnaptysBio Announces Third Quarter 2020 Financial Results GlobeNewswire Inc

Oct 27, 2020

11:53AM EDT Wedbush Upgrades AnaptysBio to Outperform, Raises Price Target to $35 Benzinga

Oct 26, 2020

08:05AM EDT AnaptysBio, GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration Benzinga

08:00AM EDT AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology GlobeNewswire Inc

Oct 14, 2020

02:33PM EDT Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Allscripts Healthcare Solutions Shares Jump Benzinga

12:13PM EDT Mid-Day Market Update: Crude Oil Rises 1.5%; Cyclerion Therapeutics Shares Plummet Benzinga

10:33AM EDT Shares of clinical-stage biotechnology company AnaptysBio, Inc. (ANAB) are rising more than 28% Wednesday morning after announcing positive topline data from the phase II study of its drug candidate imsidolimab in moderate-to-severe generalized pustular psoriasis. RTTNews

10:22AM EDT Why AnaptysBio's Stock Is Trading Higher Today Benzinga

10:14AM EDT Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Tops Q3 Expectations Benzinga

10:01AM EDT Benzinga's Top Upgrades, Downgrades For October 14, 2020 Benzinga

07:58AM EDT Guggenheim Upgrades AnaptysBio to Buy, Announces $36 Price Target Benzinga

Oct 13, 2020

09:01AM EDT AnaptysBio Reports Positive Topline Data From GALLOP Phase 2 Clinical Trial Of Imsidolimab In Moderate-To-Severe Generalized Pustular Psoriasis Benzinga

09:00AM EDT AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 GlobeNewswire Inc

Sep 11, 2020

04:05PM EDT AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare GlobeNewswire Inc

Sep 1, 2020

07:36PM EDT Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AnaptysBio, Inc. (NASDAQ: ANAB) on behalf of long-term stockholders. Our investigation concerns whether the board of directors of AnaptysBio have breached their fiduciary duties to the company. GlobeNewswire Inc

Aug 24, 2020

09:30AM EDT Shuman Glenn & Stecker Investigates AnaptysBio, Inc. Business Wire

Aug 10, 2020

08:15AM EDT AnaptysBio Q2 Loss Per Share $0.79 Vs Loss $0.89 Last Year RTTNews

08:11AM EDT AnaptysBio Says 'We plan to re-assess the etokimab program following review of the complete week 16 data from the ECLIPSE trial later this year.' Benzinga

08:09AM EDT AnaptysBio Reports Top-Line Data From Interim Analysis Of ECLIPSE Phase 2 Clinical Trial Of Etokimab; Says 'Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis' Benzinga

08:07AM EDT AnaptysBio Q2 EPS $(0.79) Up From $(0.89) YoY Benzinga

08:05AM EDT AnaptysBio Announces Second Quarter 2020 Financial Results and GlobeNewswire Inc

08:00AM EDT AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE GlobeNewswire Inc

Aug 5, 2020

04:05PM EDT AnaptysBio to Present at The 2020 Wedbush GlobeNewswire Inc

Jul 31, 2020

08:34AM EDT AnaptysBio Appoints Dr. Paul F. Lizzul As Chief Medical Officer Benzinga

08:32AM EDT AnaptysBio Appoints Paul Lizzul As Chief Medical Officer RTTNews

08:30AM EDT AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Paul F. Lizzul, M.D., Ph.D. as Chief Medical Officer. GlobeNewswire Inc

Jul 15, 2020

08:30AM EDT AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer. GlobeNewswire Inc